{"product_id":"glpg-business-model-canvas","title":"Galapagos Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalapagos: Unveiling the Business Model Canvas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the core engine of Galapagos's innovation with a detailed look at their Business Model Canvas. This comprehensive breakdown reveals their unique approach to value creation, customer relationships, and revenue streams. Equip yourself with this strategic blueprint to fuel your own business growth and competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Biotech Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalapagos actively pursues strategic alliances with other pharmaceutical and biotechnology firms. These partnerships are crucial for bolstering research capabilities, speeding up the drug development pipeline, and broadening its therapeutic portfolio.  For instance, Galapagos has a significant collaboration with BridGene Biosciences aimed at advancing small molecule drug discovery within the oncology sector.\u003c\/p\u003e\n\u003cp\u003eThese collaborations frequently take the form of co-development agreements, licensing deals, and joint ventures. Such structures enable the sharing of vital resources, specialized knowledge, and financial risks, which is essential for successfully bringing novel medicines to the market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalapagos actively partners with academic and research institutions to tap into pioneering scientific advancements, essential for developing innovative drug candidates. These collaborations grant access to specialized knowledge, cutting-edge technologies, and a deeper grasp of disease pathways, thereby fueling innovation and speeding up the discovery of new therapeutic targets.\u003c\/p\u003e\n\u003cp\u003eA prime example of this strategy is Galapagos' collaboration with Moffitt Cancer Center. This partnership specifically aims to build robust manufacturing capabilities for CAR-T therapies, demonstrating a commitment to translating research breakthroughs into tangible treatment solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations (CDMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalapagos relies on Contract Development and Manufacturing Organizations (CDMOs) to produce its advanced cell therapy candidates, crucial for their decentralized manufacturing strategy. These collaborations are vital for ensuring the high-quality and efficient production of intricate biological treatments, ultimately speeding up patient access. \u003c\/p\u003e\n\u003cp\u003eKey CDMO partners for Galapagos' decentralized CAR-T manufacturing include industry leaders like Thermo Fisher Scientific, Landmark Bio, Excellos, Catalent, and CELLforCURE by Seqens. This network of specialized partners underscores Galapagos' commitment to robust and scalable production capabilities, essential for bringing innovative therapies to market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Investors and Equity Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGalapagos has secured significant backing from strategic investors and equity partners, crucial for fueling its ambitious research and development pipeline. These collaborations not only inject vital capital but also offer invaluable market insights and access, accelerating the journey from discovery to commercialization of novel therapies.\u003c\/p\u003e\n\u003cp\u003eA prime example of such a partnership is with Gilead Sciences, Inc. Gilead's equity investment and their comprehensive Option, License and Collaboration Agreement underscore the strategic importance of these relationships. This collaboration, active in recent years, has been instrumental in advancing Galapagos' drug candidates through clinical trials and towards market approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGilead Sciences Investment:\u003c\/strong\u003e Gilead Sciences made a substantial equity investment in Galapagos, demonstrating strong confidence in its scientific platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCollaboration Agreement:\u003c\/strong\u003e The Option, License and Collaboration Agreement with Gilead provides Galapagos with significant funding and strategic support for its R\u0026amp;D programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFunding R\u0026amp;D:\u003c\/strong\u003e These partnerships are essential for covering the high costs associated with developing new medicines, from early-stage research to late-stage clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Strategic partners can also provide crucial pathways to global markets, enhancing the commercial reach of Galapagos' innovative treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Platform Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGalapagos actively partners with technology and platform providers to bolster its innovative drug discovery and development pipeline. These collaborations grant access to cutting-edge tools and specialized methodologies, crucial for the company's forward-thinking strategy.\u003c\/p\u003e\n\u003cp\u003eFor instance, Galapagos has collaborated with Lonza, leveraging their Cocoon® platform for cell therapy manufacturing. This type of partnership is vital for accessing advanced capabilities that might not be feasible to develop in-house, thereby accelerating the path from research to patient.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess to Advanced Tools:\u003c\/strong\u003e Partnerships provide specialized technology platforms, enhancing drug discovery and development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProprietary Technologies:\u003c\/strong\u003e Collaborations can offer access to unique target discovery or manufacturing technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLonza Collaboration:\u003c\/strong\u003e The partnership with Lonza for the Cocoon® platform exemplifies this strategic approach.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccelerated Innovation:\u003c\/strong\u003e Leveraging external expertise speeds up the development of novel therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Biopharma Innovation and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalapagos' key partnerships are foundational to its business model, enabling access to crucial research, development, and manufacturing capabilities. These alliances, including collaborations with BridGene Biosciences for oncology drug discovery and Moffitt Cancer Center for CAR-T therapy manufacturing, are vital for expanding its therapeutic offerings and accelerating innovation.\u003c\/p\u003e\n\u003cp\u003eThe company leverages collaborations with academic institutions to tap into cutting-edge scientific advancements, ensuring a robust pipeline of innovative drug candidates. Furthermore, partnerships with CDMOs like Thermo Fisher Scientific and Catalent are essential for the high-quality, decentralized production of complex cell therapies, facilitating patient access.\u003c\/p\u003e\n\u003cp\u003eStrategic financial backing, notably from Gilead Sciences through equity investments and a comprehensive collaboration agreement, provides critical funding and market insights. These relationships are instrumental in advancing Galapagos' drug candidates through clinical trials and towards commercialization, underscoring the symbiotic nature of its partnerships.\u003c\/p\u003e\n\u003cp\u003eGalapagos also partners with technology providers like Lonza, utilizing their Cocoon® platform for advanced cell therapy manufacturing. This strategic engagement with external expertise and advanced tools is key to accelerating the development of novel therapies and maintaining a competitive edge in the biopharmaceutical landscape.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eKey Partners\u003c\/th\u003e\n\u003cth\u003ePurpose\u003c\/th\u003e\n\u003cth\u003eExample Collaboration\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\/Pharma\u003c\/td\u003e\n\u003ctd\u003eBridGene Biosciences\u003c\/td\u003e\n\u003ctd\u003eDrug Discovery \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eOncology small molecule discovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Research\u003c\/td\u003e\n\u003ctd\u003eMoffitt Cancer Center\u003c\/td\u003e\n\u003ctd\u003eManufacturing Capabilities\u003c\/td\u003e\n\u003ctd\u003eCAR-T therapy manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eThermo Fisher Scientific, Catalent, Lonza\u003c\/td\u003e\n\u003ctd\u003eManufacturing \u0026amp; Technology\u003c\/td\u003e\n\u003ctd\u003eDecentralized cell therapy production, Cocoon® platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Investors\u003c\/td\u003e\n\u003ctd\u003eGilead Sciences\u003c\/td\u003e\n\u003ctd\u003eFunding \u0026amp; Strategic Support\u003c\/td\u003e\n\u003ctd\u003eOption, License and Collaboration Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA structured framework that visually maps out the key components of a business, including customer segments, value propositions, channels, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eIt provides a holistic view of how a business creates, delivers, and captures value, facilitating strategic planning and innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Galapagos Business Model Canvas offers a structured approach to identify and address critical business challenges by visually mapping out key elements, thereby alleviating the pain of disjointed strategies.\u003c\/p\u003e\n\u003cp\u003eIt simplifies complex business thinking, providing a clear, actionable framework that relieves the pain of overwhelming strategic planning and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Target Identification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalapagos’s central activity revolves around its advanced target discovery platform, a cornerstone for identifying new drug candidates. This involves deep dives into research and preclinical work to unravel disease pathways and pinpoint key molecular targets for treatment, especially for conditions like inflammation and fibrosis.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Galapagos continued to invest heavily in R\u0026amp;D, with a significant portion allocated to its discovery engine. The company’s pipeline, built on this platform, includes several promising candidates in early-stage development, underscoring the platform's ongoing success in generating novel therapeutic opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical and Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalapagos dedicates substantial resources to advancing its drug candidates through preclinical testing and comprehensive clinical trials, including Phase 1, 2, and 3. This critical stage involves meticulous study design and execution to evaluate the safety, efficacy, and appropriate dosing of investigational medicines, particularly those targeting conditions with high unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Galapagos continued to advance its pipeline, with a focus on the strategic initiation of clinical development for new CAR-T candidates. The company's commitment to expanding its portfolio is evident in its plans to further progress these programs and other pipeline assets throughout 2025 and 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalapagos' key activities in manufacturing and supply chain management are centered on its innovative decentralized approach for cell therapies. This involves building and overseeing a network of manufacturing partners, often Contract Development and Manufacturing Organizations (CDMOs), to produce fresh, stem-like early memory CAR-T cells.\u003c\/p\u003e\n\u003cp\u003eThe primary goal is to achieve a rapid vein-to-vein time, which is critical for the efficacy of these complex biological treatments. This necessitates meticulous management of collaborations and a highly efficient, robust supply chain to ensure timely delivery of personalized therapies to patients.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, the company continued to expand its CDMO network, aiming to support the growing demand for its CAR-T therapies across multiple geographies. This expansion is crucial for scaling production while maintaining the stringent quality and speed required for patient treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGalapagos' key activities include meticulously navigating the intricate regulatory pathways to secure necessary approvals from health authorities. This is crucial for bringing innovative treatments to patients. For instance, securing approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) involves extensive data submission and rigorous review processes.\u003c\/p\u003e\n\u003cp\u003eBeyond initial approval, ensuring market access for these approved therapies is paramount. This involves proactive engagement with healthcare systems and payers. The goal is to facilitate patient access to Galapagos' transformative treatments, making sure they can reach those who need them.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Navigation:\u003c\/strong\u003e Successfully obtaining marketing authorizations from agencies like the FDA and EMA for new drug applications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Strategies:\u003c\/strong\u003e Developing and implementing plans to ensure reimbursement and patient access within national healthcare systems and private insurance markets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealth Technology Assessment (HTA):\u003c\/strong\u003e Engaging with HTA bodies to demonstrate the value and cost-effectiveness of Galapagos' medicines, a critical step for market entry in many European countries.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Portfolio Building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGalapagos actively safeguards its groundbreaking research through a comprehensive intellectual property strategy, primarily utilizing patents to protect its innovative discoveries. This ensures a competitive edge and secures the value of its scientific advancements.\u003c\/p\u003e\n\u003cp\u003eA core activity involves the strategic development of a strong pipeline of novel medicines. This is achieved through a dual approach: nurturing internal research and development efforts while simultaneously pursuing external growth via strategic acquisitions and licensing agreements.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2023, Galapagos reported significant R\u0026amp;D expenditure, underscoring its commitment to pipeline expansion. The company also highlighted several key licensing deals and collaborations aimed at broadening its therapeutic reach and strengthening its intellectual property portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Securing patents for novel drug candidates and platform technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Development:\u003c\/strong\u003e Investing in internal R\u0026amp;D to advance new medicines through clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Partnerships:\u003c\/strong\u003e Engaging in licensing and acquisition activities to enhance the pipeline and intellectual property assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech's Strategic Focus: Discovery, Development, Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalapagos' key activities are centered on its advanced target discovery platform, which fuels its research and preclinical efforts to identify novel drug candidates. The company also focuses on advancing these candidates through rigorous clinical trials, including the strategic initiation of CAR-T programs in 2024.\u003c\/p\u003e\n\u003cp\u003eManufacturing and supply chain management are critical, particularly for its decentralized cell therapy approach, which relies on a network of CDMOs to ensure rapid vein-to-vein times. Furthermore, Galapagos actively navigates complex regulatory pathways for approvals and develops market access strategies to ensure patient access to its therapies.\u003c\/p\u003e\n\u003cp\u003eIntellectual property protection through patents is a core activity, alongside strategic pipeline development via internal R\u0026amp;D and external collaborations, licensing, and acquisitions. The company's commitment to R\u0026amp;D was evident in its significant expenditures in 2023, supporting pipeline expansion and strengthening its IP portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2024 Focus\/Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Discovery \u0026amp; R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eIdentifying novel drug candidates and unraveling disease pathways.\u003c\/td\u003e\n\u003ctd\u003eContinued investment in discovery engine; pipeline advancement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development\u003c\/td\u003e\n\u003ctd\u003eAdvancing drug candidates through preclinical and clinical trials.\u003c\/td\u003e\n\u003ctd\u003eInitiation of new CAR-T candidates; progression of other pipeline assets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eDecentralized production of cell therapies via CDMOs.\u003c\/td\u003e\n\u003ctd\u003eExpansion of CDMO network to meet growing demand.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory \u0026amp; Market Access\u003c\/td\u003e\n\u003ctd\u003eSecuring approvals and ensuring patient access to therapies.\u003c\/td\u003e\n\u003ctd\u003eNavigating regulatory pathways; engaging with healthcare systems.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property \u0026amp; Pipeline Growth\u003c\/td\u003e\n\u003ctd\u003eProtecting discoveries and expanding therapeutic reach.\u003c\/td\u003e\n\u003ctd\u003ePatent protection; licensing and acquisition activities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Galapagos Business Model Canvas preview you see is the actual document you will receive upon purchase. This means you're getting a direct look at the complete, ready-to-use file, ensuring no surprises and full transparency. Once your order is processed, you'll have instant access to this exact same professional and comprehensive Business Model Canvas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611233010041,"sku":"glpg-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/glpg-business-model-canvas.png?v=1754753435","url":"https:\/\/growthsharematrix.com\/products\/glpg-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}